| BID | 9.11 | ASK | 9.45 | ||
| Open | 9.42 | Previous Close | 9.20 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 22.00 | Analyst Rating | — 0.00 | |
| Potential % | 133.55 | Finscreener Ranking | ★★★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | ★ — - | |
| Price Range Ratio 52W % | 24.42 | Earnings Rating | Buy | |
| Market Cap | 39.53M | Earnings Date | 28th Mar 2012 | |
| Alpha | 0.03 | Standard Deviation | 0.18 | |
| Beta | -0.46 |
Today's Price Range 9.429.42 | 52W Range 7.8114.40 | 5 Year PE Ratio Range -98.1027.90 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.36% | ||
| 1 Month | -5.61% | ||
| 3 Months | -1.88% | ||
| 6 Months | -11.55% | ||
| 1 Year | -31.34% | ||
| 3 Years | -39.26% | ||
| 5 Years | 54.43% | ||
| 10 Years | 38.51% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 3.67 | |||
ROE last 12 Months | 27.66 | |||
ROA (5Y Avg) | 2.63 | |||
ROA last 12 Months | 24.14 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | -0.10 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.60 | ||||
| 2.03 | ||||
| -28.75 | ||||
| 26.90 | ||||
| -82.00 | ||||
| -0.47 | ||||
| 2.03 | ||||
| 4.60 | ||||
| - | ||||
| Forward PE | 23.87 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| 0.12 | ||||
| 0.14 | ||||
| 107.80 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| 79.30 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1 396 490.00 | ||||
| -0.33 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2011 | - | -0.35 | - |
| Q03 2011 | - | -0.99 | - |
| Q02 2011 | - | -0.04 | - |
| Q01 2011 | - | -0.31 | - |
| Q04 2010 | - | 0.53 | - |
| Q03 2010 | - | 0.62 | - |
| Q02 2010 | - | 0.04 | - |
| Q01 2010 | - | -0.02 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2007 QR | - | - | - |
| 3/2008 QR | - | - | - |
| 12/2020 FY | 0.15 | 0.00 | - |
| 12/2021 FY | 0.40 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 233 |
| Shares Outstanding | 4.20K |
| Shares Float | 2.07M |
| Trades Count | 12 |
| Dollar Volume | 2.20K |
| Avg. Volume | 2.38K |
| Avg. Weekly Volume | 2.21K |
| Avg. Monthly Volume | 1.78K |
| Avg. Quarterly Volume | 3.14K |
Daxor Corporation (AMEX: DXR) stock closed at 9.42 per share at the end of the most recent trading day (a 2.39% change compared to the prior day closing price) with a volume of 233.0000 shares and market capitalization of 39.53M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 750 people. Daxor Corporation CEO is Michael Feldschuh.
The one-year performance of Daxor Corporation stock is -31.34%, while year-to-date (YTD) performance is 2.84%. DXR stock has a five-year performance of 54.43%. Its 52-week range is between 7.81 and 14.4041, which gives DXR stock a 52-week price range ratio of 24.42%
Daxor Corporation currently has a PE ratio of 8.60, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of -28.75, a price to cashflow ratio of 26.90, a PEG ratio of -, a ROA of 24.14%, a ROC of -% and a ROE of 27.66%. The company’s profit margin is 79.30%, its EBITDA margin is -%, and its revenue ttm is $-1 396 490.00 , which makes it $-0.33 revenue per share.
Of the last four earnings reports from Daxor Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Daxor Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Daxor Corporation is — (0), with a target price of $22, which is +133.55% compared to the current price. The earnings rating for Daxor Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Daxor Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Daxor Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 31.99, ATR14 : 0.29, CCI20 : -173.53, Chaikin Money Flow : -0.21, MACD : -0.09, Money Flow Index : 37.61, ROC : -3.66, RSI : 42.81, STOCH (14,3) : 21.52, STOCH RSI : 0.30, UO : 36.63, Williams %R : -78.48), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Daxor Corporation in the last 12-months were: Feldschuh Michael (Buy at a value of $19 500), Goudie Joy (Buy at a value of $2 925)
Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
CEO: Michael Feldschuh
Telephone: +1 212 330-8500
Address: 350 Fifth Avenue, New York 10118, NY, US
Number of employees: 750
